Clinical trials: Chinese Population
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Stroke
Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
The purpose of this multicenter study is to investigate the extra-/intra-cranial atherosclerosis distribution pattern in chinese populations with transient ischemic attack and ischemic stroke and analyze the influencing factors…
- Trial name
- NCT02397655
- Where
- China
- Volunteers
- 12,012 people
- Sponsor
- Xuanwu Hospital, Beijing
Partially Edentulous Jaw
Study on OsseoSpeed™ TX Implants in the Upper Jaw in a Chinese Population
The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX implants in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior maxilla…
- Trial name
- NCT01389245
- Testing
- OsseoSpeed™ TX
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Dentsply Sirona Implants and Consumables
COPD
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
This study is a phase III clinical study to assess the efficacy and safety of Revefenacin inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to placebo in a population of Chinese subjects…
- Trial name
- NCT05046795
- Testing
- Revefenacin 175 mcg in 3 ML Inhalation Solution
- Where
- 35 sites in China
- Volunteers
- 258 people
- Sponsor
- Mylan Pharma UK Ltd.
Diabetes Mellitus, Type 2
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus…
- Trial name
- NCT01030952
- Testing
- Nateglinide, Acarbose
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.
- Trial name
- NCT01646255
- Testing
- Rotigotine, L-dopa
- Where
- 24 sites in China
- Volunteers
- 346 people
- Sponsor
- UCB Pharma
Solar Lentigo
Safety and Efficacy of High-Intensity Macrofocused Ultrasound for Solar Lentigo in Chinese Population
This trial is a single-center, prospective study. The study proposes to recruit 20 patients with solar lentigo on both sides of the face.
- Trial name
- NCT06288607
- Testing
- High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nasolabial Folds in Chinese Population
Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds
The purpose of this study is to determine the safety and efficacy of using Restylane Perlane compared to Restylane for correction of moderate to severe nasolabial folds (NLF) in a Chinese population.
- Trial name
- NCT02432742
- Testing
- Restylane Perlane, Restylane
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Galderma R&D
Nasolabial Folds in Chinese Population
Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds
This is a randomized, split face, multicenter study to evaluate the efficacy and safety of Restylane Defyne compared to Restylane in correction of NLFs.
- Trial name
- NCT03003130
- Testing
- Restylane Defyne, Restylane
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Galderma R&D
Aortic Stenosis, Symptomatic Aortic Stenosis
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
To evaluate the safety and effectiveness of the SAPIEN XT (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are…
- Conditions
- Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
- Trial name
- NCT03314857
- Testing
- SAPIEN XT THV with the NovaFlex+ delivery system
- Where
- 3 sites in China
- Volunteers
- 67 people
- Sponsor
- Edwards Lifesciences
Aortic Stenosis, Symptomatic Aortic Stenosis
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are…
- Conditions
- Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
- Trial name
- NCT03466918
- Testing
- SAPIEN 3 THV with the Commander delivery system
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Edwards Lifesciences
Partially Edentulous Jaw
Study on OsseoSpeed™ TX Narrow Implants in the Lower Jaw in a Chinese Population
The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 3mm diameter implant in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the…
- Trial name
- NCT01473355
- Testing
- OsseoSpeed™ TX
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Healthy Participants
A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions
A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under…
- Trial name
- NCT07147257
- Testing
- CHS-1420, HUMIRA®
- Where
- China
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide in Peri-Operative COPD
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general…
- Trial name
- NCT01943552
- Testing
- ipratropium bromide
- Where
- 9 sites in China
- Volunteers
- 192 people
- Sponsor
- Boehringer Ingelheim
Stress Ulcer Prophylaxis
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.
- Trial name
- SUP (NCT02157376)
- Testing
- Esomeprazole, Cimetidine
- Where
- 15 sites in China
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Adenomatous Polyp of Colon
CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method.
- Conditions
- Colorectal Cancer, Adenomatous Polyp of Colon, Polyps, Other Disease/Injury
- Trial name
- RESEPT (NCT02540850)
- Where
- 4 sites in China
- Volunteers
- 1,031 people, healthy volunteers welcome
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Allergic Rhinitis
Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Primary aim is to evaluate the efficacy of specific immunotherapy with Pangramin SLIT HDM-mix compared to placebo in the treatment of House Dust Mite (HDM) induced rhinitis with or without asthma.
- Trial name
- NCT01603056
- Testing
- Pangramin SLIT HDM mix.
- Where
- China
- Volunteers
- 617 people
- Sponsor
- ALK-Abelló A/S
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in…
- Trial name
- NCT01486966
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Crohn's Disease
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.
- Trial name
- NCT03234907
- Testing
- Vedolizumab IV
- Where
- 29 sites in China
- Volunteers
- 215 people
- Sponsor
- Takeda